INBPOTCPharmaceutical PreparationsFiscal year ends June 30
INTEGRATED BIOPHARMA INC
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 25, 2026
$0.18+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $5.59M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2026
Gross margin
1.8%−13.1 pts over 5 years
Operating margin
-6.2%−15.3 pts over 5 years
Net margin
-6.5%−19.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -19.3% | -4.7% | -7.1% | +0.4% | |
| Gross profit | -85.6% | -41.8% | -39.0% | -17.5% | |
| Free cash flow | -52.2% | -7.1% | -20.1% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | -32.9% | 78.6% | -15.0% | |
| Return on assets | 16.1% | 33.1% | -11.3% | |
| Current ratio | 1.13 | 1.95 | 3.00 | |
| Debt to equity | -0.90 | 0.10 | – | |
| Net debt to EBITDA | 1.46× | 0.20× | – | |
| Interest coverage | 3.5× | 22.6× | -225.4× | |
| Inventory turnover | 5.2× | 4.6× | 4.7× | |
| Capex to revenue | 0.7% | 0.5% | 0.8% | |
| Diluted shares | 30M | 32M | 31M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Integrated Biopharma generated $9.57M from operations and spent $1.69M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$9.57M
Used
$1.69M
Capital expenditure$1.69M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-6.5%
×Asset turnover1.75×
×Equity multiplier1.32×
=Return on equity, FY2026-15.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | -6.5% | 1.75× | 1.32× | -15.0% |
| FY2025 | 1.5% | 2.13× | 1.29× | 4.1% |
| FY2024 | 0.2% | 1.92× | 1.38× | 0.6% |
| FY2023 | -0.1% | 1.97× | 1.37× | -0.2% |
| FY2022 | 6.8% | 2.22× | 1.54× | 23.3% |
| FY2021 | 12.6% | 2.63× | 2.37× | 78.6% |
| FY2020 | 7.8% | 2.47× | 5.37× | 103.2% |
| FY2019 | 3.4% | 2.91× | -10.28× | -101.0% |
| FY2018 | 1.6% | 2.94× | -2.67× | -12.2% |
| FY2017 | 5.0% | 3.22× | -2.04× | -32.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
3of 8 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero-$2.84M
- Cash generatingOperating cash flow above zero$1.24M
- Return on assets improvedROA up on the prior year3.1% → -11.4%
- Earnings backed by cashOperating cash flow above net income$1.24M vs -$2.84M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.42 → 3.00
- No dilutionShare count did not rise31M → 31M
- Gross margin improvedGross margin up on the prior year10.23% → 1.82%
- More efficientAsset turnover rose2.07 → 1.76